Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...

In recent trading, Lightwave Logic Inc (LWLG) stock price has shown some volatility, fluctuating 8.55% over the last five trades and 11.88% over the past 30 trades. This represents a notable shift ...

Shares of Sage Therapeutics, Inc. SAGE were down 4.3% on Oct. 8 after the company announced disappointing top-line data from ...

Sage Therapeutics’ share price fell 11% to $6 in pre-market activity on Tuesday, after it announced disappointing top-line ...

Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results ...

Lightwave Logic, Inc. (NASDAQ:LWLG) is no longer a reflexivity case to the extent that the general market isn't in a bearish spot, and they are moving to raise capital at fine prices. Revenues ...

Sage Therapeutics is a sell due to failure of SAGE-324 in essential tremors and dalzanemdor's poor performance in Parkinson's ...

(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's ...

Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues ...

On Monday, Lightwave Logic Inc (LWLG) stock saw a decline, ending the day at $2.76 which represents a decrease of $-0.19 or -6.44% from the prior close of $2.95. The stock opened at $2.95 and touched ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Lightwave Logic, Inc. (NASDAQ: LWLG), a technology platform company leveraging its proprietary electro-optic (EO) polymers to ...